APR 13, 2017 06:00 AM PDT

The Pandora's box of molecular diagnostics: Genomic analysis of uterine lavage fluid detects early endometrial cancers

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Icahn School of Medicine at Mount Sinai Departments of Genetics and Genomic Sciences, Pediatrics, Obstetrics/Gynecology & Reproductive Sciences and Oncological Sciences
    Biography
      John A. Martignetti, MD, PhD, an expert in human genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai, as the Network Director of the Laboratory for Translational Research at the WCHN Biomedical Research Institute. Under this collaboration, Dr. Martignetti's well-established bedside to bench cancer research methodology will be extended to patients at Danbury, Norwalk and New Milford hospitals leading to more personalized and successful therapeutic strategies. He will work closely with the oncology physicians and research scientists across WCHN to build on their nationally recognized efforts.

    Abstract:

    Endometrial cancer is the most common gynecologic malignancy in the United States and both the incidence and associated mortality are rising. When detected early, endometrial cancer survival rates are dramatically improved. Despite this, no screening methods have been developed which can effectively detect either pre-malignant lesions or early-stage cancers. We conducted a prospective study to analyze the effectiveness of molecular analysis of uterine lavage fluid, taken at the time of evaluation for a definitive tissue-based diagnosis, to assess the use of targeted next generation sequencing (NGS) for detecting endometrial carcinomas. The women in this study were primarily either experiencing abnormal uterine bleeding or had abnormal pelvic ultrasound findings and were being evaluated by hysteroscopy and curettage for a tissue diagnosis. We detected somatic mutations in all women who were later diagnosed with endometrial cancer, even microscopic stage IA, grade 1. In addition, we also identified that half of the women in our study who did not have clinical evidence of cancer, nonetheless possessed a significant landscape of driver mutations. Our findings therefore suggest the apparently inimicable possibilities of a genomics- based approach for endometrial cancer screening and the discovery of prevalent driver mutations in clinically-defined non-cancerous tissue.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    DEC 10, 2019 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 10, 2019 09:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 10, 2019TIME: 9:00am PST, 12:00pm EST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid dif...
    JUL 31, 2019 09:00 AM PDT
    C.E. CREDITS
    JUL 31, 2019 09:00 AM PDT
    DATE: July 31, 2019TIME: 9:00am PT, 12:00pm ET The choroid plexus, which makes up the blood-cerebrospinal fluid barrier in the central nervous system (CNS), lines the ventricle...
    Loading Comments...
    Show Resources